cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aerovate Therapeutics Inc
1 own
1 watching
Current Price
$0
$-0.22
(-1.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
411.64M
52-Week High
52-Week High
30.79
52-Week Low
52-Week Low
11.13
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization411.64M
icon52-Week High30.79
icon52-Week Low11.13
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Aerovate Therapeutics Inc do?
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Aerovate Therapeutics Inc make?
News & Events about Aerovate Therapeutics Inc.
Ticker Report
1month ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Hunter Gillies sold 4,000 shares of Aerovate Therapeutics stock in a transaction that occurred on Friday, April 21st. The stock was sold at an average price of $19.50, for a total transaction of $78,000.00. Following the ...
Zolmax
2 months ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of the companys stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $19.39, for a total value of $290,850.00. The transaction was disclosed in a document filed with the ...
Globe Newswire
3 months ago
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced that Company management will ...
Zolmax
4 months ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of Aerovate Therapeutics stock in a transaction on Wednesday, February 1st. The stock was sold at an average price of $22.68, for a total transaction of $340,200.00. The sale was disclosed in a legal filing ...
Globe Newswire
4 months ago
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as ...
Frequently Asked Questions
Frequently Asked Questions
What is Aerovate Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aerovate Therapeutics Inc shares?
plus_minus_icon
How can I buy Aerovate Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aerovate Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aerovate Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aerovate Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aerovate Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aerovate Therapeutics Inc?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.22
(-1.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00